Sabby Management’s Ocular Therapeutix OCUL Stock Holding History

Sabby Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-142,000	Closed	-$1.42M	–	200
2021 Q3	$1.42M	Buy	142,000 +122,783	+639%	+$1.38M	0.19%	71
2021 Q2	$273K	Buy	19,217 +9,967	+108%	+$152K	0.04%	122
2021 Q1	$152K	Buy	+9,250	New	+$178K	0.03%	143
2016 Q4	–	Sell	-38,100	Closed	-$262K	–	321
2016 Q3	$262K	Buy	+38,100	New	+$232K	0.01%	261
2016 Q1	–	Sell	-90,000	Closed	-$843K	–	339
2015 Q4	$843K	Sell	90,000 -15,190	-14%	-$164K	0.05%	203
2015 Q3	$1.48M	Buy	105,190 +5,190	+5%	+$104K	0.06%	194
2015 Q2	$2.1M	Buy	+100,000	New	+$2.48M	0.08%	160
2015 Q1	–	Sell	-98,951	Closed	-$2.33K	–	316
2014 Q4	$2.33K	Sell	98,951 -198,156	-67%	-$3.33M	0.07%	114
2014 Q3	$4.45K	Buy	+297,107	New	+$4.39M	0.17%	67

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Sabby Management's OCUL Position: Q4 2021 in Review

Sabby Management sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 142,000 shares — an estimated $1.42M sold.

Sabby Management first reported a position in OCUL in Q3 2014 and held it in 9 quarters. The position peaked at $2.1M in Q2 2015. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

Sabby Management reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
Sabby Management sold 142,000 Ocular Therapeutix shares in Q4 2021, an estimated $1.42M.
Sabby Management first reported a position in Ocular Therapeutix in Q3 2014 and held it in 9 quarters.
Sabby Management's Ocular Therapeutix position peaked at $2.1M in Q2 2015.
140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.